| Gastric Cancer Management and Outcomes | Lifetime | 23 | KR 2 | 99.88 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 15 | KR 1 | 99.84 |
| Gastrointestinal disorders and treatments | Lifetime | 60 | KR 1 | 99.62 |
| Metastasis and carcinoma case studies | Lifetime | 43 | KR 5 | 99.24 |
| Colorectal Cancer Treatments and Studies | Lifetime | 89 | KR 5 | 99.61 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 147 | KR 12 | 99.38 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 240 | KR 7 | 99.42 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 146 | KR 11 | 99.20 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 489 | KR 13 | 98.79 |
| HER2/EGFR in Cancer Research | Lifetime | 343 | KR 9 | 98.52 |
| Lung Cancer Treatments and Mutations | Lifetime | 995 | KR 40 | 98.09 |
| Cancer Treatment and Pharmacology | Lifetime | 786 | KR 8 | 97.92 |
| Esophageal Cancer Research and Treatment | Lifetime | 646 | KR 10 | 96.80 |
| Fibroblast Growth Factor Research | Lifetime | 328 | KR 2 | 95.45 |
| Liver physiology and pathology | Lifetime | 664 | KR 9 | 95.35 |
| Colorectal and Anal Carcinomas | Lifetime | 895 | KR 47 | 95.29 |
| Cancer Mechanisms and Therapy | Lifetime | 671 | KR 18 | 93.87 |
| Chemotherapy-related skin toxicity | Lifetime | 441 | KR 2 | 88.23 |
| Soft tissue tumors and treatment | Lifetime | 529 | KR 9 | 76.20 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 2 | KR 1 | 99.89 |
| Metastasis and carcinoma case studies | 2021-2025 | 1 | KR 1 | 99.49 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 8 | KR 1 | 99.87 |
| Gastrointestinal disorders and treatments | 2021-2025 | 12 | KR 1 | 98.53 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 159 | KR 3 | 99.37 |
| Fibroblast Growth Factor Research | 2021-2025 | 24 | KR 1 | 95.40 |
| HER2/EGFR in Cancer Research | 2021-2025 | 201 | KR 11 | 96.83 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 421 | KR 6 | 93.67 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 376 | KR 18 | 95.34 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 377 | KR 13 | 93.66 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 651 | KR 67 | 93.59 |
| Peptidase Inhibition and Analysis | 2021-2025 | 598 | KR 13 | 90.22 |
